Skip to main content
Fig. 4 | Retrovirology

Fig. 4

From: Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection

Fig. 4

CCR4 antagonist treatment does not enhance vaccination efficacy. C57BL/6 mice were chronically infected with FV (>6 weeks) and therapeutically vaccinated either with PBS or functionalized CaP nanoparticles. In addition mice were injected with 2.5 µg CCR4 antagonist 4 h prior to vaccination (a) or in addition on day 1, 2, 3, and 4 post vaccination (b). 7 days later mice were sacrificed and analyzed for the percentages of Foxp3+ CD4+ T cells, CD43+ granzyme B expressing CD8+ T cells in the spleen are depicted. Infectious centers indicating the viral load in the spleen 7 days after vaccination in combination with 2.5 µg CCR4 antagonist 4 h prior or also on day 1, 2, 3 and 4 post vaccination (b) are shown. Results of one experiment are shown. Bars represent mean ± SEM. One-way ANOVA followed by Bonferoni’s multiple comparison test was performed to analyze statistics of multiple group sets

Back to article page

Retrovirology

ISSN: 1742-4690

Contact us